At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02561 VISEN PHARMA-B
Not Yet Opened 06-25 16:08:08
19.810
+0.450
+2.32%
High20.000
Low18.890
Vol4.50K
Open19.000
D1 Closing19.360
Amplitude5.73%
Mkt Cap2.26B
Tradable Cap2.26B
Total Shares114.00M
T/O86.64K
T/O Rate0.00%
Tradable Shares114.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
VISEN PHARMA-B Repurchases 4,000 Shares for Approximately HK$76,800
Visen Pharmaceuticals is a holding company mainly engaged in developing and commercializing disruptive endocrine therapies. The Company's main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years old. The navepegritide is a disease repair therapy used to treat children with cartilage dysplasia aged 2 to 10 years old. The palopegteriparatide is a treatment method used to treat adult hypoparathyroidism. The Company is in the late stage of research and development, and its products are close to commercialization.